Search

Your search keyword '"van Rossum I"' showing total 16 results
Start Over Author "van Rossum I" Database OAIster
16 results on '"van Rossum I"'

1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Author

Wannan, CMJ, Nelson, B, Addington, J, Allott, K, Anticevic, A, Arango, C, Baker, JT, Bearden, CE, Billah, T, Bouix, S, Broome, MR, Buccilli, K, Cadenhead, KS, Calkins, ME, Cannon, TD, Cecci, G, Chen, EYH, Cho, KIK, Choi, J, Clark, SR, Coleman, MJ, Conus, P, Corcoran, CM, Cornblatt, BA, Diaz-Caneja, CM, Dwyer, D, Ebdrup, BH, Ellman, LM, Fusar-Poli, P, Galindo, L, Gaspar, PA, Gerber, C, Glenthoj, LB, Glynn, R, Harms, MP, Horton, LE, Kahn, RS, Kambeitz, J, Kambeitz-Ilankovic, L, Kane, JM, Kapur, T, Keshavan, MS, Kim, S-W, Koutsouleris, N, Kubicki, M, Kwon, JS, Langbein, K, Lewandowski, KE, Light, GA, Mamah, D, Marcy, PJ, Mathalon, DH, McGorry, PD, Mittal, VA, Nordentoft, M, Nunez, A, Pasternak, O, Pearlson, GD, Perez, J, Perkins, DO, Powers, AR, Roalf, DR, Sabb, FW, Schiffman, J, Shah, JL, Smesny, S, Spark, J, Stone, WS, Strauss, GP, Tamayo, Z, Torous, J, Upthegrove, R, Vangel, M, Verma, S, Wang, J, Winter-van Rossum, I, Wolf, DH, Wolff, P, Wood, SJ, Yung, AR, Agurto, C, Alvarez-Jimenez, M, Amminger, P, Armando, M, Asgari-Targhi, A, Cahill, J, Carrion, RE, Castro, E, Cetin-Karayumak, S, Chakravarty, MM, Cho, YT, Cotter, D, D'Alfonso, S, Ennis, M, Fadnavis, S, Fonteneau, C, Gao, C, Gupta, T, Gur, RE, Gur, RC, Hamilton, HK, Hoftman, GD, Jacobs, GR, Jarcho, J, Ji, JL, Kohler, CG, Lalousis, PA, Lavoie, S, Lepage, M, Liebenthal, E, Mervis, J, Murty, V, Nicholas, SC, Ning, L, Penzel, N, Poldrack, R, Polosecki, P, Pratt, DN, Rabin, R, Eichi, HR, Rathi, Y, Reichenberg, A, Reinen, J, Rogers, J, Ruiz-Yu, B, Scott, I, Seitz-Holland, J, Srihari, VH, Srivastava, A, Thompson, A, Turetsky, BI, Walsh, BC, Whitford, T, Wigman, JTW, Yao, B, Yuen, HP, Ahmed, U, Byun, AJS, Chung, Y, Do, K, Hendricks, L, Huynh, K, Jeffries, C, Lane, E, Langholm, C, Lin, E, Mantua, V, Santorelli, G, Ruparel, K, Zoupou, E, Adasme, T, Addamo, L, Adery, L, Ali, M, Auther, A, Aversa, S, Baek, S-H, Bates, K, Bathery, A, Bayer, JMM, Beedham, R, Bilgrami, Z, Birch, S, Bonoldi, I, Borders, O, Borgatti, R, Brown, L, Bruna, A, Carrington, H, Castillo-Passi, RI, Chen, J, Cheng, N, Ching, AE, Clifford, C, Colton, B-L, Contreras, P, Corral, S, Damiani, S, Done, M, Estrade, A, Etuka, BA, Formica, M, Furlan, R, Geljic, M, Germano, C, Getachew, R, Goncalves, M, Haidar, A, Hartmann, J, Jo, A, John, O, Kerins, S, Kerr, M, Kesselring, I, Kim, H, Kim, N, Kinney, K, Krcmar, M, Kotler, E, Lafanechere, M, Lee, C, Llerena, J, Markiewicz, C, Matnejl, P, Maturana, A, Mavambu, A, Mayol-Troncoso, R, McDonnell, A, McGowan, A, McLaughlin, D, McIlhenny, R, McQueen, B, Mebrahtu, Y, Mensi, M, Hui, CLM, Suen, YN, Wong, SMY, Morrell, N, Omar, M, Partridge, A, Phassouliotis, C, Pichiecchio, A, Politi, P, Porter, C, Provenzani, U, Prunier, N, Raj, J, Ray, S, Rayner, V, Reyes, M, Reynolds, K, Rush, S, Salinas, C, Shetty, J, Snowball, C, Tod, S, Turra-Farina, G, Valle, D, Veale, S, Whitson, S, Wickham, A, Youn, S, Zamorano, F, Zavaglia, E, Zinberg, J, Woods, SW, Shenton, ME, Wannan, CMJ, Nelson, B, Addington, J, Allott, K, Anticevic, A, Arango, C, Baker, JT, Bearden, CE, Billah, T, Bouix, S, Broome, MR, Buccilli, K, Cadenhead, KS, Calkins, ME, Cannon, TD, Cecci, G, Chen, EYH, Cho, KIK, Choi, J, Clark, SR, Coleman, MJ, Conus, P, Corcoran, CM, Cornblatt, BA, Diaz-Caneja, CM, Dwyer, D, Ebdrup, BH, Ellman, LM, Fusar-Poli, P, Galindo, L, Gaspar, PA, Gerber, C, Glenthoj, LB, Glynn, R, Harms, MP, Horton, LE, Kahn, RS, Kambeitz, J, Kambeitz-Ilankovic, L, Kane, JM, Kapur, T, Keshavan, MS, Kim, S-W, Koutsouleris, N, Kubicki, M, Kwon, JS, Langbein, K, Lewandowski, KE, Light, GA, Mamah, D, Marcy, PJ, Mathalon, DH, McGorry, PD, Mittal, VA, Nordentoft, M, Nunez, A, Pasternak, O, Pearlson, GD, Perez, J, Perkins, DO, Powers, AR, Roalf, DR, Sabb, FW, Schiffman, J, Shah, JL, Smesny, S, Spark, J, Stone, WS, Strauss, GP, Tamayo, Z, Torous, J, Upthegrove, R, Vangel, M, Verma, S, Wang, J, Winter-van Rossum, I, Wolf, DH, Wolff, P, Wood, SJ, Yung, AR, Agurto, C, Alvarez-Jimenez, M, Amminger, P, Armando, M, Asgari-Targhi, A, Cahill, J, Carrion, RE, Castro, E, Cetin-Karayumak, S, Chakravarty, MM, Cho, YT, Cotter, D, D'Alfonso, S, Ennis, M, Fadnavis, S, Fonteneau, C, Gao, C, Gupta, T, Gur, RE, Gur, RC, Hamilton, HK, Hoftman, GD, Jacobs, GR, Jarcho, J, Ji, JL, Kohler, CG, Lalousis, PA, Lavoie, S, Lepage, M, Liebenthal, E, Mervis, J, Murty, V, Nicholas, SC, Ning, L, Penzel, N, Poldrack, R, Polosecki, P, Pratt, DN, Rabin, R, Eichi, HR, Rathi, Y, Reichenberg, A, Reinen, J, Rogers, J, Ruiz-Yu, B, Scott, I, Seitz-Holland, J, Srihari, VH, Srivastava, A, Thompson, A, Turetsky, BI, Walsh, BC, Whitford, T, Wigman, JTW, Yao, B, Yuen, HP, Ahmed, U, Byun, AJS, Chung, Y, Do, K, Hendricks, L, Huynh, K, Jeffries, C, Lane, E, Langholm, C, Lin, E, Mantua, V, Santorelli, G, Ruparel, K, Zoupou, E, Adasme, T, Addamo, L, Adery, L, Ali, M, Auther, A, Aversa, S, Baek, S-H, Bates, K, Bathery, A, Bayer, JMM, Beedham, R, Bilgrami, Z, Birch, S, Bonoldi, I, Borders, O, Borgatti, R, Brown, L, Bruna, A, Carrington, H, Castillo-Passi, RI, Chen, J, Cheng, N, Ching, AE, Clifford, C, Colton, B-L, Contreras, P, Corral, S, Damiani, S, Done, M, Estrade, A, Etuka, BA, Formica, M, Furlan, R, Geljic, M, Germano, C, Getachew, R, Goncalves, M, Haidar, A, Hartmann, J, Jo, A, John, O, Kerins, S, Kerr, M, Kesselring, I, Kim, H, Kim, N, Kinney, K, Krcmar, M, Kotler, E, Lafanechere, M, Lee, C, Llerena, J, Markiewicz, C, Matnejl, P, Maturana, A, Mavambu, A, Mayol-Troncoso, R, McDonnell, A, McGowan, A, McLaughlin, D, McIlhenny, R, McQueen, B, Mebrahtu, Y, Mensi, M, Hui, CLM, Suen, YN, Wong, SMY, Morrell, N, Omar, M, Partridge, A, Phassouliotis, C, Pichiecchio, A, Politi, P, Porter, C, Provenzani, U, Prunier, N, Raj, J, Ray, S, Rayner, V, Reyes, M, Reynolds, K, Rush, S, Salinas, C, Shetty, J, Snowball, C, Tod, S, Turra-Farina, G, Valle, D, Veale, S, Whitson, S, Wickham, A, Youn, S, Zamorano, F, Zavaglia, E, Zinberg, J, Woods, SW, and Shenton, ME

Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

2. Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies

Author

Worker, A, Berthert, P, Lawrence, AJ, Kia, SM, Arango, C, Dinga, R, Galderisi, S, Glenthoj, B, Kahn, RS, Leslie, A, Murray, RM, Pariante, CM, Pantelis, C, Weiser, M, Winter-van Rossum, I, Mcguire, P, Dazzan, P, Marquand, AF, Worker, A, Berthert, P, Lawrence, AJ, Kia, SM, Arango, C, Dinga, R, Galderisi, S, Glenthoj, B, Kahn, RS, Leslie, A, Murray, RM, Pariante, CM, Pantelis, C, Weiser, M, Winter-van Rossum, I, Mcguire, P, Dazzan, P, and Marquand, AF

Abstract

There is currently no quantifiable method to predict long-term clinical outcomes in patients presenting with a first episode of psychosis. A major barrier to developing useful markers for this is biological heterogeneity, where many different pathological mechanisms may underly the same set of symptoms in different individuals. Normative modelling has been used to quantify this heterogeneity in established psychotic disorders by identifying regions of the cortex which are thinner than expected based on a normative healthy population range. These brain atypicalities are measured at the individual level and therefore potentially useful in a clinical setting. However, it is still unclear whether alterations in individual brain structure can be detected at the time of the first psychotic episode, and whether they are associated with subsequent clinical outcomes. We applied normative modelling of cortical thickness to a sample of first-episode psychosis patients, with the aim of quantifying heterogeneity and to use any pattern of cortical atypicality to predict symptoms and response to antipsychotic medication at timepoints from baseline up to 95 weeks (median follow-ups = 4). T1-weighted brain magnetic resonance images from the GAP and OPTiMiSE samples were processed with Freesurfer V6.0.0 yielding 148 cortical thickness features. An existing normative model of cortical thickness (n = 37,126) was adapted to integrate data from each clinical site and account for effects of gender and site. Our test sample consisted of control participants (n = 149, mean age = 26, SD = 6.7) and patient data (n = 295, mean age = 26, SD = 6.7), this sample was used for estimating deviations from the normative model and subsequent statistical analysis. For each individual, the 148 cortical thickness features were mapped to centiles of the normative distribution and converted to z-scores reflecting the distance from the population mean. Individual cortical thickness metrics of +/- 2.6 standar

Published
2023

3. Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies.

Author

Worker, A., Berthert, P., Lawrence, A.J., Kia, S.M., Arango, C., Dinga, R., Galderisi, S., Glenthøj, B., Kahn, R.S., Leslie, A., Murray, R.M., Pariante, C.M., Pantelis, C., Weiser, M., Winter-van Rossum, I., McGuire, P., Dazzan, P., Marquand, A.F., Worker, A., Berthert, P., Lawrence, A.J., Kia, S.M., Arango, C., Dinga, R., Galderisi, S., Glenthøj, B., Kahn, R.S., Leslie, A., Murray, R.M., Pariante, C.M., Pantelis, C., Weiser, M., Winter-van Rossum, I., McGuire, P., Dazzan, P., and Marquand, A.F.

Abstract

Contains fulltext : 300063.pdf (Publisher’s version ) (Open Access), There is currently no quantifiable method to predict long-term clinical outcomes in patients presenting with a first episode of psychosis. A major barrier to developing useful markers for this is biological heterogeneity, where many different pathological mechanisms may underly the same set of symptoms in different individuals. Normative modelling has been used to quantify this heterogeneity in established psychotic disorders by identifying regions of the cortex which are thinner than expected based on a normative healthy population range. These brain atypicalities are measured at the individual level and therefore potentially useful in a clinical setting. However, it is still unclear whether alterations in individual brain structure can be detected at the time of the first psychotic episode, and whether they are associated with subsequent clinical outcomes. We applied normative modelling of cortical thickness to a sample of first-episode psychosis patients, with the aim of quantifying heterogeneity and to use any pattern of cortical atypicality to predict symptoms and response to antipsychotic medication at timepoints from baseline up to 95 weeks (median follow-ups = 4). T1-weighted brain magnetic resonance images from the GAP and OPTiMiSE samples were processed with Freesurfer V6.0.0 yielding 148 cortical thickness features. An existing normative model of cortical thickness (n = 37,126) was adapted to integrate data from each clinical site and account for effects of gender and site. Our test sample consisted of control participants (n = 149, mean age = 26, SD = 6.7) and patient data (n = 295, mean age = 26, SD = 6.7), this sample was used for estimating deviations from the normative model and subsequent statistical analysis. For each individual, the 148 cortical thickness features were mapped to centiles of the normative distribution and converted to z-scores reflecting the distance from the population mean. Individual cortical thickness metrics of +/- 2.6 standar

Published
2023

6. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design

Author

Nasib, L.G. (Lyliana G.), Sommer, I.E. (Iris E.), Winter-van Rossum, I. (Inge), de Vries, J. (Jacqueline), Gangadin, S.S. (Shiral S.), Oomen, P.P. (Priscilla P.), Judge, G. (Gurmeet), Blom, R.E. (Renske E.), Luykx, J.J. (Jurjen J.), Beveren, N.J.M. (Nico) van, Veen, N.D. (Natalie D.), Kroken, R.A. (Rune A.), Johnsen, E.L. (Erik L.), Nasib, L.G. (Lyliana G.), Sommer, I.E. (Iris E.), Winter-van Rossum, I. (Inge), de Vries, J. (Jacqueline), Gangadin, S.S. (Shiral S.), Oomen, P.P. (Priscilla P.), Judge, G. (Gurmeet), Blom, R.E. (Renske E.), Luykx, J.J. (Jurjen J.), Beveren, N.J.M. (Nico) van, Veen, N.D. (Natalie D.), Kroken, R.A. (Rune A.), and Johnsen, E.L. (Erik L.)

Abstract

BACKGROUND: The symptom severity of a substantial group of schizophrenia patients (30-40%) does not improve through pharmacotherapy with antipsychotic medication, indicating a clear need for new treatment options to improve schizophrenia outcome. Meta-analyses, genetic studies, randomized controlled trials, and post-mortem studies suggest that immune dysregulation plays a role in the pathophysiology of schizophrenia. Some anti-inflammatory drugs have shown beneficial effects on the symptom severity of schizophrenia patients. Corticosteroids are effective in various chronic inflammatory and autoimmune disorders. Prednisolone, a potent glucocorticosteroid, has minor mineral-corticosteroid potencies and can adequately pass the blood-brain barrier a

Published
2020
Full Text
View/download PDF

7. Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

Author

Tognin, S, van Hell, HH, Merritt, K, Winter-van Rossum, I, Bossong, MG, Kempton, MJ, Modinos, G, Fusar-Poli, P, Mechelli, A, Dazzan, P, Maat, A, de Haan, L, Crespo-Facorro, B, Glenthoj, B, Lawrie, SM, McDonald, C, Gruber, O, van Amelsvoort, T, Arango, C, Kircher, T, Nelson, B, Galderisi, S, Bressan, R, Kwon, JS, Weiser, M, Mizrahi, R, Sachs, G, Maatz, A, Kahn, R, McGuire, P, Tognin, S, van Hell, HH, Merritt, K, Winter-van Rossum, I, Bossong, MG, Kempton, MJ, Modinos, G, Fusar-Poli, P, Mechelli, A, Dazzan, P, Maat, A, de Haan, L, Crespo-Facorro, B, Glenthoj, B, Lawrie, SM, McDonald, C, Gruber, O, van Amelsvoort, T, Arango, C, Kircher, T, Nelson, B, Galderisi, S, Bressan, R, Kwon, JS, Weiser, M, Mizrahi, R, Sachs, G, Maatz, A, Kahn, R, and McGuire, P

Abstract

In the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.

Published
2020

9. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

Author

Pandit, R., Cianci, D., ter Hark, S. E., Winter-van Rossum, I., Ebdrup, B. H., Broberg, B. V., Garcia-Portilla, M. P., Bobes, J., Vinkers, C. H., Kahn, R. S., Guloksuz, S., Huitema, A. D.R., Luykx, J. J., Pandit, R., Cianci, D., ter Hark, S. E., Winter-van Rossum, I., Ebdrup, B. H., Broberg, B. V., Garcia-Portilla, M. P., Bobes, J., Vinkers, C. H., Kahn, R. S., Guloksuz, S., Huitema, A. D.R., and Luykx, J. J.

Abstract

Objective: Antipsychotic-induced weight gain (AiWG) is a debilitating adverse effect of most antipsychotics. First-episode psychosis patients are particularly vulnerable to the detrimental consequences of AiWG. Amisulpride has good efficacy and tolerability. We here aimed to identify the phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients. Method: Data were collected from the Optimization of Treatment and Management of Schizophrenia in Europe trial. Multivariable regression models with various phenotypic variables (N = 305) were performed with absolute AiWG and clinically relevant AiWG (≥7% AiWG) as outcomes. Results: Four weeks of amisulpride treatment increased body weight from 69.7 to 72.4 kg (P < 0.001). In the regression model of absolute AiWG, unemployment (β = 0.94, P = 0.016), younger age (β = −0.07, P = 0.031) and absence of current comorbid major depression disorder (β = −1.61, P = 0.034) were positively associated with absolute AiWG. In the regression model of clinically relevant AiWG, unemployment (OR = 2.83, P = 0.001), schizophreniform disorder (OR = 2.00, P = 0.025) and low baseline weight (OR = 0.97, P = 0.032) increased the likelihood of clinically relevant AiWG. Conclusions: Clinicians prescribing amisulpride should consider the relatively high susceptibility to AiWG in unemployed first-episode patients with psychosis, in particular young subjects with a diagnosis of schizophreniform disorder. We advise to carefully monitor these patients and, when needed, implement weight-reducing strategies.

Published
2019

10. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

Author

Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, Luykx, J J, Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, and Luykx, J J

Published
2019

11. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

Author

Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, Luykx, J J, Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, and Luykx, J J

Published
2019

12. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

Author

Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, Luykx, J J, Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, and Luykx, J J

Published
2019

13. Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)

Author

TN Onderwijs, Biostatistiek Onderzoek, Onderzoeksgroep 9, Brain, MS Neonatologie, Onderzoeksgroep 11, Apotheek Onderzoek, Cancer, Neurogenetica, Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, Luykx, J J, TN Onderwijs, Biostatistiek Onderzoek, Onderzoeksgroep 9, Brain, MS Neonatologie, Onderzoeksgroep 11, Apotheek Onderzoek, Cancer, Neurogenetica, Pandit, R, Cianci, D, Ter Hark, S E, Winter-van Rossum, I, Ebdrup, B H, Broberg, B V, Garcia-Portilla, M P, Bobes, J, Vinkers, C H, Kahn, R S, Guloksuz, S, Huitema, A D R, and Luykx, J J

Published
2019

15. Country report INDONESIA - MFS II EVALUATIONS

Author

Klaver, D.C., Kusters, C.S.L., Pradhan, M., Vigh, M., Groot Bruinderink, M., van Rossum, I., Böhnke, L., Wallaart, K., Malamas, S., Berkhout, E., Ni Wayan Suriasatini, Sikoki, B., Ginting, M.B., Mulia, M., Ningsih, K., Pujiastuti, S., Dwi Andari, B., Suprobo, N., Priyahita, W., Sihombing, R.R., Rokhmatulloh, S.W., Rosita, I., Wieriks, M., Smidt, H., Nugroho, K., Prasetyo, K., Larastiti, C., Amir, S., Sutikno, Klaver, D.C., Kusters, C.S.L., Pradhan, M., Vigh, M., Groot Bruinderink, M., van Rossum, I., Böhnke, L., Wallaart, K., Malamas, S., Berkhout, E., Ni Wayan Suriasatini, Sikoki, B., Ginting, M.B., Mulia, M., Ningsih, K., Pujiastuti, S., Dwi Andari, B., Suprobo, N., Priyahita, W., Sihombing, R.R., Rokhmatulloh, S.W., Rosita, I., Wieriks, M., Smidt, H., Nugroho, K., Prasetyo, K., Larastiti, C., Amir, S., and Sutikno

Abstract

This report on Indonesia is one of a series of evaluation reports, consisting of ten reports in total, reflecting the results of the jointly-organised MFS II evaluation: - eight country reports (India, Bangladesh, Ethiopia, Uganda, Indonesia, DR Congo, Liberia, Pakistan); - a synthesis report (covering the eight country studies); and - a report with the results of the international lobbying and advocacy programmes. This series of reports assessed the 2011-2015 contribution of the Dutch Co-Financing System (MFS II) towards achieving the Millennium Development Goals, strengthening international civil society, setting the international agenda and changing decision-makers’ policy and practice, with the ultimate goal of reducing structural poverty. On July 2nd, 2015, the reports were approved by the independent steering committee (see below), which concluded that they meet the quality standards of validity, reliability and usefulness set by the Ministry of Foreign Affairs.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results